Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression.

  • Martin, Alberto, 1974-
  • Salvador, Fernando
  • Moreno-Bueno, Gema
  • Floristán, Alfredo
  • Ruiz Herguido, Cristina
  • Cuevas, Eva P. Cuevas
  • Morales, Saleta
  • Santos, Vanessa Sonia
  • Csiszar, Katalin
  • Dubus, Pierre
  • Haigh, Jody J.
  • Bigas Salvans, Anna
  • Portillo, Francisco
  • Cano, Amparo
Lysyl oxidase-like 2 (LOXL2) is involved in a wide range of physiological and pathological processes, including fibrosis and tumor progression, implicating intracellular and extracellular functions. To explore the specific in vivo role of LOXL2 in physiological and tumor contexts, we generated conditional gain- and loss-of-function mouse models. Germ-line deletion of Loxl2 promotes lethality in half of newborn mice mainly associated to congenital heart defects, while Loxl2 overexpression triggers male sterility due to epididymal dysfunction caused by epithelial disorganization, fibrosis and acute inflammation. Remarkably, when challenged to chemical skin carcinogenesis, Loxl2-overexpressing mice increased tumor burden and malignant progression, while Loxl2-deficient mice exhibit the opposite phenotypes. Loxl2 levels in premalignant tumors negatively correlate with expression of epidermal differentiation markers and components of the Notch1 pathway. We show that LOXL2 is a direct repressor of NOTCH1. Additionally, we identify an exclusive expression pattern between LOXL2 and members of the canonical NOTCH1 pathway in human HNSCC. Our data identify for the first time novel LOXL2 roles in tissue homeostasis and support it as a target for SCC therapy., This work has been supported by grants from the Spanish Ministry of Economy and Innovation SAF2010-21143 (AC), SAF2010-20175 (GMB), SAF2013-44739-R (AC and FP) and CONSOLIDERINGENIO 2010 CSD2007-00017 (AC); the AICR (12-1057) (AC and AM), the Spanish Instituto de Salud Carlos III [(RETIC-RD12/0036/0007 (AC), RETICCRD12/0036/0054 (AB), PI13/00132 (GMB)], Comunidad de Madrid (S2010/BMD- 2303) (AC and GMB) and AECC-2011 (GMB). AM and EPC are founded by postdoctoral contracts from S2010/BMD-2303 and AICR grants, respectively; FS was founded by a Jae-pre contract from the CSIC; and SM and VS are founded by technician contracts from the RETIC-RD12/0036/0007 and AICR grants, respectively
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Loss of Snail2 favors skin tumor progression by promoting the recruitment of myeloid progenitors

  • Villarejo, Ana
  • Molina-Martínez, Patricia
  • Montenegro, Yenny
  • Moreno-Bueno, Gema
  • Morales, Saleta
  • Santos, Vanesa
  • Gridley, Tom
  • Pérez-Moreno, Mirna A.
  • Peinado, Héctor
  • Portillo, Francisco
  • Calés, Carmela
  • Cano, Amparo
Snail2 is a zinc finger transcription factor involved in driving epithelial to mesenchymal transitions. Snail2 null mice are viable, but display defects in melanogenesis, gametogenesis and hematopoiesis, and are markedly radiosensitive. Here, using mouse genetics, we have studied the contributions of Snail2 to epidermal homeostasis and skin carcinogenesis. Snail2 −/− mice presented a defective epidermal terminal differentiation and, unexpectedly, an increase in number, size and malignancy of tumor lesions when subjected to the two-stage mouse skin chemical carcinogenesis protocol, compared with controls. Additionally, tumor lesions from Snail2 −/− mice presented a high inflammatory component with an elevated percentage of myeloid precursors in tumor lesions that was further increased in the presence of the anti-inflammatory agent dexamethasone. In vitro studies in Snail2 null keratinocytes showed that loss of Snail2 leads to a decrease in proliferation indicating a non-cell autonomous role for Snail2 in the skin carcinogenic response observed in vivo. Bone marrow (BM) cross-reconstitution assays between Snail2 wild-type and null mice showed that Snail2 absence in the hematopoietic system fully reproduces the tumor behavior of the Snail2 null mice and triggers the accumulation of myeloid precursors in the BM, blood and tumor lesions. These results indicate a new role for Snail2 in preventing myeloid precursors recruitment impairing skin chemical carcinogenesis progression., Spanish Ministry of Science and Innovation (SAF2010-21143; Consolider-Ingenio 2007-CS00017; SAF2013-44739R); Worldwode Research Cancer (formerly AICR: Associaton for International Cancer Research) (12-1057); Instituto de Salud Carlos III (RETIC-RD12/0036/0007) to A.C. and F.P.; Comunidad de Madrid (S2010/BMD-2302 to A.C. and G.M.-B.); National Institutes of Health (NIH R01HD034883 to T.G.)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression

  • Martín, Alberto
  • Salvador, Fernando
  • Moreno-Bueno, Gema
  • Floristán, Alfredo
  • Cuevas, Eva P.
  • Morales, Saleta
  • Santos, Vanesa
  • Csiszar, Katalin
  • Portillo, Francisco
  • Cano, Amparo
Lysyl oxidase-like 2 (LOXL2) is involved in a wide range of physiological and pathological processes, including fibrosis and tumor progression, implicating intracellular and extracellular functions. To explore the specific in vivo role of LOXL2 in physiological and tumor contexts, we generated conditional gain- and loss-of-function mouse models. Germ-line deletion of Loxl2 promotes lethality in half of newborn mice mainly associated to congenital heart defects, while Loxl2 overexpression triggers male sterility due to epididymal dysfunction caused by epithelial disorganization, fibrosis and acute inflammation. Remarkably, when challenged to chemical skin carcinogenesis, Loxl2-overexpressing mice increased tumor burden and malignant progression, while Loxl2-deficient mice exhibit the opposite phenotypes. Loxl2 levels in premalignant tumors negatively correlate with expression of epidermal differentiation markers and components of the Notch1 pathway. We show that LOXL2 is a direct repressor of NOTCH1. Additionally, we identify an exclusive expression pattern between LOXL2 and members of the canonical NOTCH1 pathway in human HNSCC. Our data identify for the first time novel LOXL2 roles in tissue homeostasis and support it as a target for SCC therapy., This work has been supported by grants from the Spanish Ministry of Economy and Innovation SAF2010-21143 (AC), SAF2010-20175 (GMB), SAF2013-44739-R (AC and FP) and CONSOLIDER-INGENIO 2010 CSD2007-00017 (AC); the AICR (12-1057) (AC and AM), the Spanish Instituto de Salud Carlos III [(RETIC-RD12/0036/0007 (AC), RETICC-RD12/0036/0054 (AB), PI13/00132 (GMB)], Comunidad de Madrid (S2010/BMD-2303) (AC and GMB) and AECC-2011 (GMB). AM and EPC are founded by postdoctoral contracts from S2010/BMD-2303 and AICR grants, respectively; FS was founded by a Jae-pre contract from the CSIC; and SM and VS are founded by technician contracts from the RETIC-RD12/0036/0007 and AICR grants, respectively., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

EMT: Present and future in clinical oncology

  • Santamaría, Patricia G.
  • Moreno-Bueno, Gema
  • Portillo, Francisco
  • Cano, Amparo
Epithelial/mesenchymal transition (EMT) has emerged as a key regulator of metastasis by facilitating tumor cell invasion and dissemination to distant organs. Recent evidences support that the reverse mesenchymal/epithelial transition (MET) is required for metastatic outgrowth; moreover, the existence of hybrid epithelial/mesenchymal (E/M) phenotypes is increasingly being reported in different tumor contexts. The accumulated data strongly support that plasticity between epithelial and mesenchymal states underlies the dissemination and metastatic potential of carcinoma cells. However, the translation into the clinics of EMT and epithelial plasticity processes presents enormous challenges and still remains a controversial issue. In this review, we will evaluate current evidences for translational applicability of EMT and depict an overview of the most recent EMT in vivo models, EMT marker analyses in human samples as well as potential EMT therapeutic approaches and ongoing clinical trials. We foresee that standardized analyses of EMT markers in solid and liquid tumor biopsies in addition to innovative tools targeting the E/M states will become promising strategies for future translation to the clinical setting., Work in our laboratories is supported by grants from the Spanish Ministerio de Economía y Competitividad SAF2013-44739-R and SAF2016-76504-R (AC and FP), the Spanish Instituto de Salud Carlos III [RETIC-RD12/0036/0007, CIBERONC-CB16/12/00295 (AC); PI13/00132, PI16/00134 (GMB)] (all of them partly supported from EUFEDER funds), and Worldwide Cancer Research (WWCR, formerly AICR) WWCR 16-0295 (AC, PGS, and FP). PGS was funded by a postdoctoral contract from the Fundacion Científica AECC and presently from WWCR 16-0295., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lysyl oxidase–like protein LOXL2 promotes lung metastasis of breast cancer

  • Salvador, Fernando
  • Martín, Alberto
  • López-Menéndez, Celia
  • Moreno-Bueno, Gema
  • Santos, Vanesa
  • Vázquez-Naharro, Alberto
  • Santamaría, Patricia G.
  • Morales, Saleta
  • Dubus, Pierre R.
  • Muinelo-Romay, Laura
  • López-López, Rafael
  • Tung, Jason C.
  • Weaver, Valerie M.
  • Portillo, Francisco
  • Cano, Amparo
The lysyl oxidase-like protein LOXL2 has been suggested to contribute to tumor progression and metastasis, but in vivo evidence has been lacking. Here we provide functional evidence that LOXL2 is a key driver of breast cancer metastasis in two conditional transgenic mouse models of PyMT-induced breast cancer. LOXL2 ablation in mammary tumor cells dramatically decreased lung metastasis, whereas LOXL2 overexpression promoted metastatic tumor growth. LOXL2 depletion or overexpression in tumor cells does not affect extracellular matrix stiffness or organization in primary and metastatic tumors, implying a function for LOXL2 independent of its conventional role in extracellular matrix remodeling. In support of this likelihood, cellular and molecular analyses revealed an association of LOXL2 action with elevated levels of the EMT regulatory transcription factor Snail1 and expression of several cytokines that promote premetastatic niche formation. Taken together, our findings established a pathophysiologic role and new function for LOXL2 in breast cancer metastasis., This work has been supported by grants from the Spanish Ministry of Economy and Innovation SAF2010-21143 (to A. Cano, F. Portillo), SAF2013-44739-R (to A. Cano, P.G. Santamaría, F. Portillo), SAF2016-76504-R (to A. Cano, C. Lopez-Menendez, P.G. Santamaría, F. Portillo), and CONSOLIDER-INGENIO 2010 CSD2007-00017 (to A. Cano), the Spanish Instituto de Salud Carlos III [(RETIC-RD12/0036/0007 to A. Cano, G. Moreno-Bueno, P.G. Santamaria, F. Portillo and CIBERONC to A. Cano, G. Moreno-Bueno, F. Portillo, R. Lopez-Lopez, L. Muinelo-Romay, PI13/00132 to G. Moreno-Bueno (all partly supported by FEDER funds)]; Worldwide Cancer Research (formerly AICR) 12-1057 to A. Cano, A. Martin, P.G. Santamaría; Worldwide Cancer Research 16-0295 to A. Cano, F. Portillo, P.G. Santamaría; Comunidad de Madrid (S2010/BMD-2303 to A. Cano, G. Moreno-Bueno); AECC-2011 to G. Moreno-Bueno; and TV3-Telemarato 2013 to G. Moreno-Bueno. A. Martin, F. Salvador, and A. Vazquez-Naharro were funded by the JAE-CSIC program, S2010/BMD-2303, SAF2013-44739-R, and Worldwide Cancer Research 12-1057 grants; P.G. Santamaría by a contract from Fundacion AECC (Spain) and, presently, by Worldwide Cancer Research 16-0295 grant; V. Santos by CSD2007-00017, Worldwide Cancer Research 12-1057 and SAF2013-44739-R grants, and S. Morales by RETIC-RD12/0036/0007 grant., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

LOXL2 drives epithelialmesenchymal transition via activation of IRE1-XBP1 signalling pathway

  • Cuevas, Eva P.
  • Eraso, Pilar
  • Mazón, María J.
  • Santos, Vanesa
  • Moreno-Bueno, Gema
  • Cano, Amparo
  • Portillo, Francisco
Epithelial-to-Mesenchymal Transition (EMT) is a key process contributing to the aggressiveness of cancer cells. EMT is triggered by activation of different transcription factors collectively known as EMT-TFs. Different cellular cues and cell signalling networks activate EMT at transcriptional and posttranscriptional level in different biological and pathological situations. Among them, overexpression of LOXL2 (lysyl oxidase-like 2) induces EMT independent of its catalytic activity. Remarkably, perinuclear/cytoplasmic accumulation of LOXL2 is a poor prognosis marker of squamous cell carcinomas and is associated to basal breast cancer metastasis by mechanisms no yet fully understood. Here, we report that overexpression of LOXL2 promotes its accumulation in the Endoplasmic Reticulum where it interacts with HSPA5 leading to activation of the IRE1-XBP1 signalling pathway of the ER-stress response. LOXL2-dependent IRE1-XBP1 activation induces the expression of several EMT-TFs: SNAI1, SNAI2, ZEB2 and TCF3 that are direct transcriptional targets of XBP1. Remarkably, inhibition of IRE1 blocks LOXL2-dependent upregulation of EMT-TFs thus hindering EMT induction., This work has been supported by grants from the Spanish Ministerio de Economía y Competividad SAF2013-44739-R and SAF2016-76504-R (AC and FP), the Spanish Instituto de Salud Carlos III [(RETIC-RD12/0036/0007 (AC), PI13/00132 (GMB), CB16/12/00295 (AC), CIBERONC (AC)] (all of them partly supported from EU-FEDER founds), and Worldwide Cancer Research (WWCR, formerly AICR) AICR 12-1057 (AC). EPC and VS were founded by postdoctoral and technician contracts, respectively, from SAF2013-44739-R and WWCR grants., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lysyl oxidase-like 3 is required for melanoma cell survival by maintaining genomic stability

  • Santamaría, Patricia G.
  • Floristán, Alfredo
  • Fontanals-Cirera, Bárbara
  • Vázquez-Naharro, Alberto
  • Santos, Vanesa
  • Morales, Saleta
  • Yuste Pérez, Lourdes
  • Peinado, Héctor
  • García-Gómez, Antonio
  • Portillo, Francisco
  • Hernando, Eva
  • Cano, Amparo
Lysyl oxidase-like 3 (LOXL3) is a member of the lysyl oxidase family comprising multifunctional enzymes with depicted roles in extracellular matrix maturation, tumorigenesis, and metastasis. In silico expression analyses followed by experimental validation in a comprehensive cohort of human cell lines revealed a significant upregulation of LOXL3 in human melanoma. We show that LOXL3 silencing impairs cell proliferation and triggers apoptosis in various melanoma cell lines. Further supporting a pro-oncogenic role in melanoma, LOXL3 favors tumor growth in vivo and cooperates with oncogenic BRAF in melanocyte transformation. Upon LOXL3 depletion, melanoma cells display a faulty DNA damage response (DDR), characterized by ATM checkpoint activation and inefficient ATR activation leading to the accumulation of double-strand breaks (DSBs) and aberrant mitosis. Consistent with these findings, LOXL3 binds to proteins involved in the maintenance of genome integrity, in particular BRCA2 and MSH2, whose levels dramatically decrease upon LOXL3 depletion. Moreover, LOXL3 is required for efficient DSB repair in melanoma cells. Our results reveal an unexpected role for LOXL3 in the control of genome stability and melanoma progression, exposing its potential as a novel therapeutic target in malignant melanoma, a very aggressive condition yet in need for more effective treatment options., A.F.M. was supported by a FPI predoctoral fellowship from the Spanish Ministry of Economy and Innovation (MINECO) (associated to SAF2013-44739-R) and by Worldwide Cancer Research (16–0295) grant. P.G.S. was a recipient of an Oncology Research Contract (AIO) from the Fundación de la Asociación Española contra el Cáncer (AECC) and is currently funded by Worldwide Cancer Research (16–0295) grant. A.V-N., V.S., S.M., and L.Y. were supported by AICR, MINECO and the Spanish Fondo de Investigaciones Sanitarias (FIS). E.H.'s laboratory is funded by the NIH (US) (R01CA155234, R01CA163891, and R21AR062239). Work in the A.C.'s laboratory is supported by grants from the MINECO (SAF2013-44739-R, SAF2016-76504-R, ConsoliderIngenio ONCOBIO CSD00C-2007-00017), Comunidad de Madrid (S2010/BMD-2303), ISCIII (RTICC-RD12/0036/0007, CIBERONCCB16/12/00295), all of them partly supported from EU-FEDER funds, and Worldwide Cancer Research UK (formerly AICR, 12-1057, and 16-0295 grants)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Lysyl oxidase-like 3 in melanoma progression

  • Bustos-Tauler, José
  • Vázquez-Naharro, Alberto
  • Yuste Pérez, Lourdes
  • Cano, Amparo
  • Santamaría, Patricia G.
Resumen del trabajo presentado al 1st PhD Research Symposium in Health Sciences and Biomedicine, celebrado en la Universidad Autónoma de Madrid el 18 de mayo de 2018., SAF2013-44739R, SAF2016-76504-R Ministerio de Economía y Competitividad (MINECO), CB16/12/00295 CIBERONC, 16-0295 Worldwide Cancer Research (WWCR), Red de Cáncer RETIC-RD12/0036/0007 (Instituto de Salud Carlos III)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

UPR: An Upstream Signal to EMT Induction in Cancer

  • Santamaría, Patricia G.
  • Mazón, María J.
  • Eraso, Pilar
  • Portillo, Francisco
© 2019 by the authors., The endoplasmic reticulum (ER) is the organelle where newly synthesized proteins enter the secretory pathway. Different physiological and pathological conditions may perturb the secretory capacity of cells and lead to the accumulation of misfolded and unfolded proteins. To relieve the produced stress, cells evoke an adaptive signalling network, the unfolded protein response (UPR), aimed at recovering protein homeostasis. Tumour cells must confront intrinsic and extrinsic pressures during cancer progression that produce a proteostasis imbalance and ER stress. To overcome this situation, tumour cells activate the UPR as a pro-survival mechanism. UPR activation has been documented in most types of human tumours and accumulating evidence supports a crucial role for UPR in the establishment, progression, metastasis and chemoresistance of tumours as well as its involvement in the acquisition of other hallmarks of cancer. In this review, we will analyse the role of UPR in cancer development highlighting the ability of tumours to exploit UPR signalling to promote epithelial-mesenchymal transition (EMT)., This research was funded by the Spanish Ministerio de Economía y Competitividad (MICINN) (SAF2013-44739-R and SAF2016-76504-R, EU-FEDER funds), Instituto de Salud Carlos III (CIBERONC 16/12/00295, EU-FEDER funds), and Worldwide Cancer Research (AICR-12-1057 and WWCR-16-0295).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

E2A Modulates stemness, metastasis, and therapeutic resistance of breast cancer

  • López-Menéndez, Celia
  • Vázquez-Naharro, Alberto
  • Santos, Vanesa
  • Dubus, Pierre R.
  • Santamaría, Patricia G.
  • Martínez-Ramírez, Ángel
  • Portillo, Francisco
  • Moreno-Bueno, Gema
  • Faraldo, Marisa M.
  • Cano, Amparo
© 2021 The Authors., Cancer stem cells (CSC) are considered responsible for tumor initiation, therapeutic resistance, and metastasis. A comprehensive knowledge of the mechanisms governing the acquisition and maintenance of cancer stemness is crucial for the development of new therapeutic approaches in oncology. E2A basic helix–loop–helix (bHLH) transcription factors are associated with epithelial–mesenchymal transition (EMT) and tumor progression, but knowledge of their functional contributions to cancer biology is still limited. Using a combination of in vivo and in vitro analyses in a novel PyMT-E2A conditional knockout mouse model and derived primary tumor cell lines, we report here an essential role of E2A in stemness, metastasis, and therapeutic resistance in breast cancer. Targeted deletion of E2A in the mammary gland impaired tumor-initiating ability and dedifferentiation potential and severely compromised metastatic competence of PyMT-driven mammary tumors. Mechanistic studies in PyMT-derived cell lines indicated that E2A actions are mediated by the upregulation of Snai1 transcription. Importantly, high E2A and SNAIL1 expression occurred in aggressive human basal-like breast carcinomas, highlighting the relevance of the E2A–Snail1 axis in metastatic breast cancer. In addition, E2A factors contributed to the maintenance of genomic integrity and resistance to PARP inhibitors in PyMT and human triple-negative breast cancer cells. Collectively, these results support the potential for E2A transcription factors as novel targets worthy of translational consideration in breast cancer., This work has been supported by grants from the Spanish Ministry of Economy and Innovation (SAF2013–44739-R, SAF2016–76504-R to A. Cano and F. Portillo), PID2019–111052RB-I00 to F. Portillo, PID2019–104644RB-I00 to G. Moreno-Bueno; the Spanish Institute of Health Carlos III (CIBERONC-CB16/12/00295 to A. Cano, G. Moreno-Bueno; all of them partly supported by FEDER funds); the AECC Scientific Foundation 2019 (PROYE19036MOR to G. Moreno-Bueno); the Association International for Cancer Research (AICR; 12–1057 to A. Cano, P.G. Santamaría); and Worldwide Cancer Research (16–0295 to A. Cano, F. Portillo, and P.G. Santamaría). A. Vázquez-Naharro was funded by a PhD contract from SAF2016–76504-R grant; V. Santos by AICR (12–1057) and SAF2016–76504-R grants; P.G. Santamaría by a research contract of the AECC Scientific Foundation, and from Worldwide Cancer Research (16–0295) and SAF2016–76504-R grants.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Loxl3 promotes melanoma progression and dissemination influencing cell plasticity and survival

  • Vázquez-Naharro, Alberto
  • Bustos-Tauler, José
  • Floristán, Alfredo
  • Yuste Pérez, Lourdes
  • Oltra, Sara S.
  • Vinyals, Antònia
  • Moreno-Bueno, Gema
  • Fabra, Àngels
  • Portillo, Francisco
  • Cano, Amparo
  • Santamaría, Patricia G.
Malignant melanoma is a highly aggressive tumor causing most skin cancer-related deaths. Understanding the fundamental mechanisms responsible for melanoma progression and therapeutic evasion is still an unmet need for melanoma patients. Progression of skin melanoma and its dissemination to local or distant organs relies on phenotypic plasticity of melanoma cells, orchestrated by EMT-TFs and microphthalmia-associated TF (MITF). Recently, melanoma phenotypic switching has been proposed to uphold context-dependent intermediate cell states benefitting malignancy. LOXL3 (lysyl oxidase-like 3) promotes EMT and has a key role in human melanoma cell survival and maintenance of genomic integrity. To further understand the role of Loxl3 in melanoma, we generated a conditional Loxl3-knockout (KO) melanoma mouse model in the context of BrafV600E-activating mutation and Pten loss. Melanocyte-Loxl3 deletion increased melanoma latency, decreased tumor growth, and reduced lymph node metastatic dissemination. Complementary in vitro and in vivo studies in mouse melanoma cells confirmed Loxl3’s contribution to melanoma progression and metastasis, in part by modulating phenotypic switching through Snail1 and Prrx1 EMT-TFs. Importantly, a novel LOXL3-SNAIL1-PRRX1 axis was identified in human melanoma, plausibly relevant to melanoma cellular plasticity. These data reinforced the value of LOXL3 as a therapeutic target in melanoma., This research was funded by grants from the Spanish Ministry of Science and Innovation MCIN (SAF2016-76504-R to A.C. and F.P., PID2019-111052RB-100 to F.P., and PID2019–104644RBI00 to G.M.-B.), Instituto de Salud Carlos III (CIBERONC-CB16/12/00295 to A.C. and G.M.-B.), all of them partly supported by EU-FEDER funds, Worldwide Cancer Research UK (grant ref. 16-0295 to A.C., F.P., and P.G.S.), and FC AECC (Grupos Estables de Investigación 2018-AECC and PROYE19036MOR to G.M.-B., and 2015-AECC to À.F., GCB15152978SOEN). S.S.O. was supported by a 2019 AECC postdoctoral contract. A.V.-N. was supported by a FPI predoctoral fellowship from MCIN (BES-2017-081082). J.B.-T. was supported by a FPI fellowship associated with SAF2013-44739-R (A.C. and F.P.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression.

  • Martin, Alberto, 1974-
  • Salvador, Fernando
  • Moreno-Bueno, Gema
  • Floristán, Alfredo
  • Ruiz Herguido, Cristina
  • Cuevas, Eva P. Cuevas
  • Morales, Saleta
  • Santos, Vanessa Sonia
  • Csiszar, Katalin
  • Dubus, Pierre
  • Haigh, Jody J.
  • Bigas Salvans, Anna
  • Portillo, Francisco
  • Cano, Amparo
Lysyl oxidase-like 2 (LOXL2) is involved in a wide range of physiological and pathological processes, including fibrosis and tumor progression, implicating intracellular and extracellular functions. To explore the specific in vivo role of LOXL2 in physiological and tumor contexts, we generated conditional gain- and loss-of-function mouse models. Germ-line deletion of Loxl2 promotes lethality in half of newborn mice mainly associated to congenital heart defects, while Loxl2 overexpression triggers male sterility due to epididymal dysfunction caused by epithelial disorganization, fibrosis and acute inflammation. Remarkably, when challenged to chemical skin carcinogenesis, Loxl2-overexpressing mice increased tumor burden and malignant progression, while Loxl2-deficient mice exhibit the opposite phenotypes. Loxl2 levels in premalignant tumors negatively correlate with expression of epidermal differentiation markers and components of the Notch1 pathway. We show that LOXL2 is a direct repressor of NOTCH1. Additionally, we identify an exclusive expression pattern between LOXL2 and members of the canonical NOTCH1 pathway in human HNSCC. Our data identify for the first time novel LOXL2 roles in tissue homeostasis and support it as a target for SCC therapy., This work has been supported by grants from the Spanish Ministry of Economy and Innovation SAF2010-21143 (AC), SAF2010-20175 (GMB), SAF2013-44739-R (AC and FP) and CONSOLIDERINGENIO 2010 CSD2007-00017 (AC); the AICR (12-1057) (AC and AM), the Spanish Instituto de Salud Carlos III [(RETIC-RD12/0036/0007 (AC), RETICCRD12/0036/0054 (AB), PI13/00132 (GMB)], Comunidad de Madrid (S2010/BMD- 2303) (AC and GMB) and AECC-2011 (GMB). AM and EPC are founded by postdoctoral contracts from S2010/BMD-2303 and AICR grants, respectively; FS was founded by a Jae-pre contract from the CSIC; and SM and VS are founded by technician contracts from the RETIC-RD12/0036/0007 and AICR grants, respectively